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Background: South Africa has made great progress in the development of HIV/AIDS testing, treatment and
prevention campaigns. Yet, it is clear that prevention and treatment campaigns alone are not enough to bring this
epidemic under control.
Discussion: News that the “Berlin patient” and the “Mississippi baby” have both been “cured” of HIV brought hope
to people living with HIV/AIDS in South Africa that a cure for HIV/AIDS is within reach. Despite the recent setbacks
announced in the “Mississippi Baby” case, protocols aimed at curing HIV/AIDS are being developed in South Africa.
However with evidence to suggest that participants in clinical trials do not understand the basic concepts in the
informed consent process, there is concern that future participants in HIV/AIDS cure research will lack comprehension
of the basic elements of future clinical trials that aims to cure HIV/AIDS and confuse research with clinical care.
Summary: Research ethics committees have an important role to play in ensuring that participants understand the
basic concepts discussed in the informed consent process, that they understand that research is not clinical care and
they are unlikely to benefit from any early phase trials seeking to cure HIV/AIDS.
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Since the days of AIDS denialism [1-3], South Africa’s
policy on HIV/AIDS has seen a transformation with the
introduction of national treatment, testing and preven-
tion campaigns [4]. Despite an increase of 1.2 million
new infections since 2008, the rate is stabilising and
access to treatment is improving [5]. By mid-2012 31.2%
of people living with HIV (PLHIV) were on treatment,
up from 16.6% in 2008 [5] and South Africa has now
passed the “tipping point” whereby more people are
accessing treatment than there are new infections [6].
This has come on foot of a successful testing campaign
which has seen rates of HIV/AIDS testing increase [7].
However with 6.4 million people (12.2% of the population)
living with HIV/AIDS [5], South Africa has the highest
number of HIV/AIDS infected individuals worldwide and
HIV/AIDS continues to be a considerable challenge facing
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unless otherwise stated.Yet life is improving for PLHIV. The availability of
anti-retroviral therapy (ART) has helped increase life
expectancy from 49.2 years prior to the availability of
ART to 60.5 years by 2011 [9]. PLHIV in South Africa
can now also expect to have 80% of normal life expect-
ancy provided they start treatment before their CD4
count drops below 200 [10]. Yet this increased provision
of treatment has a significant economic impact on the
nation. Although a recent renegotiation of a fixed dose
ARV resulted in a 40% price reduction, South Africa’s
programme is the largest treatment programme in the
world and a considerable economic burden for the state
[11]. In August 2012 the US government announced that
it would cut the United States President’s Emergency
Plan for AIDS Relief (PEPFAR) budget for South Africa
in half by 2017, at which point South Africa will have to
cover the full cost of its HIV/AIDS programme. The
process of the government taking full responsibility for
the programme has led to the closing of HIV/AIDS
treatment centres created by PEPFAR and patients’ mov-
ing to government run centres, centres which regularly
face long waiting times and medication shortages [12].
Equally problematic is the high prevalence rate [8]. Thus,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Staunton BMC Medical Ethics 2015, 16:3 Page 2 of 7
http://www.biomedcentral.com/1472-6939/16/3while treatment and prevention campaigns can reduce in-
fection rates and improve the quality of life for PLHIV,
treatment and prevention campaigns are not enough to
bring the epidemic in South Africa under control.
News that the “Berlin patient” [13] and the “Mississippi
baby” [14] have both been “cured” [15,16] of HIV likely
brought hope to PLHIV in South Africa that a cure for
HIV/AIDS is within reach, a hope which may be fuelled
by further announcements of other babies who have
also been cured [17]. Although these early reports of
HIV/AIDS cures have been somewhat dampened by the
reports of the return of HIV in the “Mississippi Baby”
[18] and the “Boston patients” [19], it appears that the
search for a cure is gaining momentum. Yet these new
developments bring a fresh set of ethical challenges that
must be addressed prior to the commencement of any
trial aimed at curing HIV/AIDS in South Africa. Of
particular concern is that at some point during such a
clinical trial, participants who are doing well on their
ART may have to go off their treatment and try some
new, experimental intervention [20]. Participants will be
asked to assume the documented risks of treatment
interruption [21], despite the very low possibility of per-
sonally benefiting in any early phase trial. The recent
setbacks of these early cases of cure illustrate that there
is a lot that is still unknown about HIV/AIDS cure
research and there is the real possibility that HIV may
return in any early phase trial.
With such unknowns, it is critical that the conduct of
the trial meets the highest ethical standards. Concerns
about trial design and the potential withdrawal of ARVs
must be discussed and addressed. Equally important is a
robust informed consent process that informs partici-
pants about these risks. However with growing evidence
in South Africa that trial participants do not understand
the information provided during the consent process
and have unrealistic expectations of possible personal
benefit, questions must be asked about the current
consent process [22-25]. This paper will examine the
informed consent process in South Africa and consider
whether additional safeguards must be put in place to
protect participants in future HIV/AIDS cure research.
In particular it will discuss the experiences of the in-
formed consent process during clinical trials in South
Africa and the potential implications they may have on
any future trial aimed at finding a cure for HIV/AIDS in
South Africa. Good ethical oversight is imperative in this
process and the role that RECs should play in this over-
sight will be discussed.
Discussion
Informed consent in South Africa: the legal landscape
Informed consent is a fundamental ethical principle that
was first codified in the Nuremberg Code in the wake ofthe Nazi experiments [26,27]. It has since been replicated
in all major ethical codes including the International
Covenant on Civil and Political Rights, the Declaration
of Helsinki and the Council for International Organisations
of Medical Sciences (CIOMS) guidelines. In South Africa,
the principle is enshrined in both the Constitution and the
National Health Act 2003, highlighting its importance.
The national research ethics guidelines Ethics in Health
Research: Principles, Structures and Processes require that
all participants must be informed of the risks and benefits,
purpose of the research and the procedures to which they
will be subjected to. These must be understood and con-
sent must be voluntary and based on this information.
The guidelines are cognisant of the fact that due to access
to health care and their education levels, many people in-
volved in research in South Africa are considered to be
vulnerable and researchers must be mindful of this vulner-
ability [28]. The clinical trial guidelines further detail what
should be included in the informed consent form (ICF).
For all clinical trials, the original signed consent form
must be kept with the trial records with one copy stored
in the patients’ records and a second copy given to the
participant to take home [29]. These guidelines have also
been supplemented with specific guidance on informed
consent in HIV Preventive Vaccine Research guidelines
[30], and other international guidelines on HIV/AIDS
research, such as the UNAIDS documents, may also be
followed in clinical trials [31]. Together, these guidelines
regulate the informed consent process in South Africa and
detail the procedure and protections which must apply to
all HIV/AIDS clinical trials.
Experiences with informed consent in South Africa
Despite ample guidelines on the matter, obtaining informed
consent in clinical trials is problematic in South Africa.
This challenge can be partly attributed to the dual purpose
of the ICF: the institution or principal investigator (PI) use
it as a tool to indemnify them from litigation as a result of
the increasingly litigious culture emerging in Western so-
cieties [32], while the ethical guidelines focus on inform-
ing the participants of all the risks associated with the
research. Thus from a document which has its origins in
promoting ethical research, it has evolved to become an
increasingly legalistic document which can be difficult to
read and decipher its contents [33]. This is challenging as
a document which is primarily designed to offer legal pro-
tection will be markedly different to a document aimed at
protecting trial participants through enabling them to
make an autonomous choice. However the South African
guidelines do require that research must be explained in
“a clear, simple and culturally appropriate manner” thus
one could assume that effort is given towards establishing
the comprehension of the ICF. Yet there is growing evi-
dence that certain key requirements of informed consent
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derstanding is lacking [22-25,34], including during HIV
vaccine trials [35,36].
The belief that consent is not voluntary or is somehow
linked to care is emerging as a common misconception
in four reported studies. In one antenatal clinic, it was
found that 93% of participants thought that they could
not withdraw from the study and 28% thought that they
would not receive care if they did not participate in the
study [22]. These findings were replicated in a similar
study in Bloemfontein where 24.2% thought they could
not withdraw at any time and 92.3% believed that they
would not receive good medical care if they did with-
draw from the study [23]. Recently it was shown that
half of those surveyed felt that they did not have a
choice about getting tested for HIV/AIDS, with many
believing that access to healthcare was contingent on
their consent to the test [25].
This lack of understanding also extends to key aspects
of the trial itself. Participants in an influenza trial
underwent a thorough informed consent procedure
that involved a community meeting, an individual discus-
sion with a study nurse and a discussion with the study
doctor on the day of the trial. Despite these repeated
consultations, participants did not understand concepts
such as randomisation or placebo and 38% of partici-
pants stated that they would not have continued with
the study if they had known that they would receive an
inactive placebo [24]. Similarly, the Bloemfontein study
found that although participants had at least 8 years of
education, they lacked a basic understanding of the clin-
ical trial and their consent could not be considered to be
informed [23].
Clearly comprehension of the often complex informa-
tion is problematic and there is evidence to suggest that
the ICFs are not understandable by the general popula-
tion. The readability of the forms have been found to be
above the education level of the general population [34].
South Africa is ranked 146th out of 148 countries for edu-
cation in light of its low primary and tertiary enrolment
rates [37] and functional illiteracy is at 16.5% [38]. There
is therefore likely to be a great imbalance in knowledge
between the researcher and the participant [39], but the
consent process does not appear to address this imbalance
and the basic concepts of the trials do not appear to be
appropriately communicated or understood.
With such challenges facing understanding of the trials,
it is unsurprising that it has been indicated that thera-
peutic misconception (TM) may be a problem in South
Africa [24], a trend which has been seen elsewhere
[40-42]. TM occurs when research participants assume
that decisions will be made based on their best clinical
interest [43]. In other words, research is confused with clin-
ical care. This is distinct from the therapeutic misestimationwhere the participant may underestimate the risk or over-
estimate the benefit [44], and therapeutic optimism which
occurs when participants are unduly optimistic about the
potential success of the research [40]. What distinguishes
TM is that participants fail to “grasp that the risks they face
from participating in research protocols are inherently dif-
ferent from those involved in receiving ordinary treatment”
[43]. They fail to appreciate that decisions will be made
based on the best interest of the trial. Thus the participant
cannot be said to be making a free, fully informed decision.
There is very little empirical data on TM and motiva-
tions to participate in a trial in South Africa, but a recent
study analysing motivations for enrolling on a Phase 3 on-
cology study has suggested that participants do expect
benefit from participating in a trial. The participants were
quite optimistic about the outcome of the trial and this is
not something which should be discouraged, but they had
a poor understanding of phase 3 research and believed
that the clinical trial posed very little risk to them [36].
These findings indicate that participants did not under-
stand the information provided during the informed con-
sent process and suggest that TM may also be an issue in
South Africa.
Informed consent and HIV/AIDS cure research
In an attempt to protect them from legal liability, dis-
closure of information by the research team is unlikely
to be a problem in South Africa. Rather the challenges
lie in comprehending this information. Researchers are
not absolved of their duty during the consent process by
simply providing the participants with information. The
ethical guidelines task the PIs with ensuring that partici-
pants understand the information provided, but must all
information be understood and what are the implications
for future HIV/AIDS cure clinical trials if they are not
satisfied?
It has been proposed that the rationale for the study,
technical issues, technical consequences, methodological
issues, practical aspects involved in personal participation,
the costs and benefits of participation in the study and the
personal implications of participation in the study should
be at least understood before involvement in a HIV vac-
cine trial [33]. These certainly should also be disclosed for
HIV/AIDS clinical trials, with a strong focus on the risks
of the trial as there are likely to be very real risks in early
phase HIV/AIDS cure research. For HIV positive individ-
uals who are otherwise healthy and on highly active ART
with an undetectable viral load who take part in a cure
trial, it is possible that they will be asked to stop taking
their treatment [20,45]. All but one of purported cases of
a “cure” for HIV has seen the disease return demonstrat-
ing the real risk that HIV may return. Furthermore in two
Boston patients who underwent treatment similar to
the Berlin patient, HIV/AIDS returned in both patients
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[46]. In addition to these documented risks is the pos-
sibility of unknown side effects associated with the
treatment. Current evidence suggests that there may
be real challenges in effectively communicating key
concepts of the trial to a study group that will be largely
drawn from a poorly educated population. Thus can we
realistically expect participants to be able to sufficiently
understand the very real risks and benefits of enrolling in
an early phase HIV/AIDS cure trial?
In addition is the real concern of TM. Africa has a
history of people willing to try unproven “cures” in the
hope of being free from HIV, thus demonstrating that
people may be willing to assume great risks in the hope
of a cure [47,48]. The pursuit of this hope may lead
them to enrol in an early phase HIV/AIDS cure trial
despite being told that there will unlikely be any individ-
ual benefit for them. TM is a real problem in early phase
research as unlike in phase 3 or 4 studies, there is un-
likely to be any direct medical benefit and the research
can be in no way linked to a participants’ clinical care. In
light of the Malan study and evidence that PLHIV will
try unproven treatments in their search for a cure, the
research team must guard against TM in HIV/AIDS
cure research. The simple use of the word “cure” as one
of the study aims may be enough to ignite the possibility
of TM. Yet participants cannot be misled; if it is hoped
that the clinical trial will find a cure for HIV, this should
be stated in the patient information leaflet and ICF, but
care must be taken around contextualising the research
to participants. The challenge for the research team is if
after a thorough informed consent process the research
team suspects that the participant is simply enrolling
because of the remote possibility of a cure, should they
be refused to join the trial?
The South African guidelines focuses on understanding
only and do not directly address this point. Horn and
Grady describe understanding as “having an accurate
grasp of the available options and the consequences of
choosing one over the other”. If a participant understands
the risks and benefits and the implications for their enrol-
ling in a study, but due to some irrational hope that they
may be cured they still enrol, technically they satisfy the
requirements of informed consent. The risks are under-
stood but are disregarded in the hope of a possible cure.
However is their desire for a cure affecting a participant’s
voluntariness? Or have they simply decided that the risks
are worth taking, despite the low probability of success?
Horn and Grady argue that TM cannot be tolerated as
it “fundamentally misrepresents the choice of research
participants”. Clearly an ability to understand the differ-
ence between clinical care and research is essential and
would fall under the requirement of understanding under
the South African guidelines. Participants who do notunderstand the difference between research and clinical
care do not understand the basic fundamentals of research
and thus cannot give free, informed consent. Yet it is less
clear for the overly optimistic participant who has decided
that the risks are worth taking despite the low probability
of success. On this point, Horn and Grady consider that
the therapeutic misestimation, whereby the participant
may underestimate the risk or overestimate the benefit,
can be tolerated when the benefit or risk is not large [44].
Turning back to the requirement of understanding in the
South African guidelines, the therapeutic misestimation is
arguably a misunderstanding as they fail to appreciate the
degree of risk or benefit, but it may also be a symptom of
being unduly optimistic. They may fully understand the
risks and the low probability of benefit, but continue to
hold onto their belief. Is undue optimism something we
should guard against particularly when their optimism is
unlikely to materialise in early phase trials or is it enough
that they understand the risks and benefits?
The role of RECs in cure research
Clearly trusting the integrity of the research team to
make an ethical decision is necessary. They are to con-
duct the trial in accordance with the protocol submitted
to the REC and South African ethical guidance and en-
sure that the elements of informed consent have been
met. The guidelines focus on the need for disclosure and
comprehension but offer little practical guidance on how
this is to be achieved. The onus is indeed on the PI to
ensure that the informed consent process meet these
criteria. The degree of therapeutic misestimation that is
acceptable before it conflicts with the requirement of
comprehension is not one that can be succulently stated
in any guidance. Rather it is a decision that must be
made by the research team. Equally, they must determine
if the participants sufficiently understands the information
provided for the consent to be valid. There is also a role
for the RECs in overseeing the ethical conduct of future
HIV/AIDS cure trials. They can provide a number of gate
keeping functions, including a role in promoting the com-
prehension of participants whilst guarding against TM.
First they must be assured that information is not sim-
ply conveyed to participants, but there is a real effort to
ensure participants understand the risks involved in the
research as well as the basic principle of informed consent.
Simplified ICFs do improve understanding [49], but they
alone may not be enough. The Coletti study evaluated a
prototype informed consent process for HIV vaccine trials
and it found that there was a substantial increase in know-
ledge and understanding of the trial [50]. A similar con-
sent form could be developed for cure research. Part of
this could also include the development of an educational
tool that can visually convey certain aspects of the re-
search. This should be in addition to the ICF and the
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tools will need to be assessed, they may go some way to-
wards improving the comprehension of participants in
clinical trials. A trial may aim to achieve a functional cure
that controls the symptoms without eradicating the virus
and a trial which is aimed at finding a sterilising cure that
leads to the complete removal of HIV from the body.
These are complex concepts that are not easily described
or understood, in particular how the virus may remain in
the body but they will no longer need to take treatment.
As the influenza study has demonstrated that repeated
consultations do not necessarily lead to improved compre-
hension, the REC should be satisfied that the research
team has a plan in place to ensure the comprehension of
participants that goes beyond the patient information leaf-
let and the ICF.
Secondly RECs must be cognisant of the risk of TM in
HIV/AIDS cure trials and ensure that the information
presented during the informed consent process should
not raise any undue expectations. While care must be
taken that the ICF clearly explains the risks of the research,
explaining the research may be challenging. It has been
suggested that “sterilising cure”, “functional cure” or “sus-
tained virological response (SVR)” could be used other than
“cure”. Such concepts however are unlikely to resonate with
participants. They are unlikely to understand the distinction
between functional and sterilising cure and SVR may not
be easily explained. “Remission” however, is a term that is
commonly used in the cancer context and does not evoke
the same hope or expectation as “cure”. It adoption in this
context has been recommended as one way in which the
TM may be kept in check [51]. It is not only more familiar
to participants, but it reflects the uncertainty in future
outcomes [16].
Finally although these measures may be of benefit in
the informed consent process, understanding of key el-
ements of the trial can still be lacking [49]. Trial coun-
sellors have reported that at times they believe that
participants do not understand the information pro-
vided, despite their claims to the contrary [52]. An
educational tool can improve comprehension, but it in
itself is not enough to satisfy that the information is
understood. Lo and Grady suggest that due to the po-
tential distorting effect that the desire for a cure may
have, understanding of the potential risks and benefits
should be assessed [45]. RECs can require such an
assessment of understanding, in much the same way as
they require the ICFs to be understandable. Such assess-
ments are not new and were used during HIV Prevention
Trials Network studies where participants were given two
opportunities to demonstrate comprehension [53]. The
development of these assessments are complicated as
reported levels of understanding can be affected by
who asks the question, the formality of the setting, thephrasing of the question [54], as well as the method of
assessment [55]. However it is crucial that efforts are
made towards the development of a tool for cure trials
to ensure that participants understand the basic con-
cepts of their involvement in a clinical trial, as well as
the benefits and risks involved in such a trial. Assur-
ance of understanding is essential. By requiring these
tools, RECs can put added protection into the system
by querying with PIs how they intend to assess under-
standing and require justification if no method is put
forward.
Unfortunately such a tool will likely only indicate in-
stances of therapeutic misconception but may not identify
cases of therapeutic misestimation or irrational hope.
Identification of such instances is likely to arise during
more informal methods of assessment that are often
adopted such as the reading of a participant’s body lan-
guage. In any case the South African guidelines are silent
on whether unduly optimistic participants should be pre-
cluded from enrolling, requiring only that the information
is understood. This will ultimately be a judgment call to
be made by the PI in consultation with other members of
the research team and in light of the potential risks that is
underestimated or the likely benefits that is overestimated.
Introducing cure trials in South Africa: the way forward
Currently there are no clinical trials ongoing in South
Africa aimed at curing HIV/AIDS but with protocols
under development, the time is now for all stakeholders
to consider these issues and develop these tools and
guidelines for such clinical trials. Once the issues which
may affect understanding or motivate participants to
enroll on such a trial are known, stakeholders can put in
place additional safeguards to ensure that the informed
consent process for clinical trials that aim to cure HIV/
AIDS is robust in South Africa.
It is clear that the informed consent process in South
Africa requires further research and analysis as the lim-
ited studies on this issue do show that there are flaws in
the process. The process is complicated by the need to
explain complex scientific issues to participants who
often have low levels of education. Thus the problems in
the informed consent system must be identified and ad-
dressed. It is important that the informed consent process
is based “on empirically valid and reliable methods that
serve the goals of informed consent, rather than on edu-
cated guesses about what and how to inform prospective
subjects” [56]. In the development of HIV/AIDS cure pro-
tocols, these challenges must be kept in mind and every
effort must be made to bolster the informed consent
process and protect participants. In particular, there is a
need for a discussion on comprehension of the informa-
tion and what must be understood before the consent can
be deemed informed. It is possible that participants will
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benefit ratio. Is it ethical to permit such participants to en-
roll on an early-phase trial?
This is not a call for new or additional guidance.
Current guidelines addresses issues such as community
participation, involvement of vulnerable populations,
children and women as well informed consent and mon-
itoring informed consent [31]. They do require that the
investigator must be assured that the participant under-
stands the information and methods to evaluate under-
standing are encouraged [31]. However in light of the
considerable risks of treatment interruption and the
relatively healthy pool that the participants are likely to
come from, there is a need for a discussion to inform both
REC members and researchers on the informed consent
process and the safeguards which must be put in place to
address concerns about understanding and TM. What
must be understood is likely to vary according to the trial
design and the intervention used, but a general discussion
on the understanding of treatment interruption as well
as whether therapeutic misestimation is permissible is
needed. This will assist the research team in determin-
ing whether the consent is informed and also help
RECs when they evaluate the information in the patient
information leaflet, the ICF and any educational tool or
assessment of understanding.
Summary
Moving forward, a discussion is necessary on the essential
elements that should be understood during the informed
consent process in South Africa. Requiring complete un-
derstanding of all the procedures involved in a HIV/AIDS
cure trial will likely result in no participant meeting the
consent criteria. A degree of misunderstanding and confu-
sion of these complex scientific concepts is to be expected
and must be acceptable. However some agreement is ne-
cessary on the degree of misunderstanding that is accept-
able and on what particular issues.
Research is currently underway at Stellenbosch University
in Cape Town to investigate the views of participants
on some of the issues raised here. In collaboration with
the University of North Carolina, Chapel Hill and the
University of Carolina, Guangzhou, this project aims
to consider the social and ethical aspects of HIV Cure
research. Findings from this study can inform these
discussions in South Africa and also inform research
teams in developing their protocols and RECs in reviewing
these submissions. In the interim, RECs should discuss the
possibility of some of the measures discussed here with the
PIs in any trial aimed at curing HIV/AIDS to increase un-
derstanding and bolster the informed consent process.
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